Our inherited thrombophilia testing is covered by Bupa. This diagnostic test enables you to predict an increased risk of venous thrombosis by testing for factor V Leiden, prothrombin G20210A. It also tests the risk of arterial thrombosis by testing homocysteine and folate metabolism, through testing of MTHFR gene as well. 

Our Heart DNA test covers 24 genetic reports that are based on qualified and accepted research, the scientific evidence is based on Genome Wide Association Studies (GWAS) and on large scale Meta-analysis studies. In addition, all markers and interpretations in our pharmacogenetic tests are based on internationally accepted and recognised guidelines, such as those adopted by the FDA and found on the prescription guidelines for anticoagulant drugs. Lastly, all our reports and interpretations have been reviewed by genetic counsellors from Guy’s and St Thomas' Hospital.

Our genotyping is done through bead-chip based microarrays. We will analyse your sample through a genotyping technology that utilises competitive allele-specific bead-chip array, which enables highly accurate bi-allelic scoring of SNPs (99.8% accurate) and indels (insertions and deletions) at specific loci across a wide range of genomic DNA samples (SNP and indel assay conversion rate 90%). This way we limit the risk of false-positive and false-negative results.